Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population

Cancer Letters

Volumn 202, Issue 1, 2003, Pages 53-59

  Wang, Li Zhong ^a   Sato, Kazunari ^a   Tsuchiya, Norihiko ^a   Yu, Jian Gang ^a   Ohyama, Chikara ^a   Satoh, Shigeru ^a   Habuchi, Tomonori ^b   Ogawa, Osamu ^b   Kato, Tetsuro ^a  

^a AKITA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Caucasian populations; Gene polymorphisms; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0344395638     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.08.001     Document Type: Article

References (28)

1. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317:1987;909-916.
2. Oesterling J.E., Martin S.K., Bergstralh E.J., Lowe F.C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 269:1993;57-60.
3. Douglas T.H., Morgan T.O., McLeod D.G., Moul J.W., Murphy G.P., Barren R. III, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer. 80:1997;107-114.
4. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1997;1445-1451.
5. Trapasso J.G., deKernion J.B., Smith R.B., Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 152:1994;1821-1825.
6. Peehl D.M. Prostate specific antigen role and function. Cancer. 75:(Suppl.):1995;2021-2026.
7. Cohen P., Graves H.C., Peehl D.M., Kamarei M., Giudice L.C., Rosenfeld R.G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75:1992;1046-1053.
8. Clemmons D.R., Dehoff M.L., Busby W.H., Bayne M.L., Cascieri M.A. Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. Endocrinology. 131:1992;890-895.
9. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M.Z., Pariente C., et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 77:1993;229-233.
10. Smith G.L., Doherty A.P., Mitchell H., Hanham I.W., Christmas T.J., Epstein R.J. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer. Lancet. 354:1999;2053-2054.
11. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:1998;563-566.
12. Chokkalingam A.P., Pollak M., Fillmore C.M., Gao Y.T., Stanczyk F.Z., Deng J., et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 10:2001;421-427.
13. Majumdar S., Diamandis E.P. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br. J. Cancer. 79:1999;1594-1602.
14. Tsuyuki D., Grass L., Diamandis E.P. Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. Eur. J. Cancer. 33:1997;1851-1854.
15. Yang Q.F., Sakurai T., Shan L., Yu Z., Yoshimura G., Suzuma T., et al. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. J. Hum. Genet. 45:2000;363-366.
16. Bharaj B., Scorilas A., Diamandis E.P., Giai M., Levesque M.A., Sutherland D.J., Hoffman B.R. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Res. Treat. 61:2000;111-119.
17. Xue W., Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A., Ingles S.A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res. 60:2000;839-841.
18. Medeiros R., Morais A., Vasconcelos A., Costa S., Pinto D., Oliveira J., et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate. 53:2002;88-94.
19. Gsur A., Preyer M., Haidinger G., Zidek T., Madersbacher S., Schatzl G., et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis. 23:2002;1647-1651.
20. Yang Q., Shan L., Segawa N., Nakamura M., Nakamura Y., Mori I., et al. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. Anticancer Res. 21:2001;197-200.
21. Habuchi T., Suzuki T., Sasaki R., Wang L., Sato K., Satoh S., et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 60:2000;305-308.
22. Habuchi T., Liqing Z., Suzuki T., Sasaki R., Tsuchiya N., Tachiki H., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60:2000;5710-5713.
23. Wang L., Habuchi T., Mitsumori K., Li Z., Kamoto T., Kinoshita H., et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int. J. Cancer. 103:2003;116-120.
24. Hermanek P., Sobin L.H. TNM Classification of Malignant Tumors. fourth ed. 1992;141-144 Springer, Berlin.
25. Ohori M., Wheeler T.M., Scardino P.T. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 74:1994;104-114.
26. Kuriyama M., Akimoto S., Akaza H., Arai Y., Usami M., Imai K., et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn. J. Clin. Oncol. 22:1992;393-399.
27. Xue W.M., Coetzee G.A., Ross R.K., Irvine R., Kolonel L., Henderson B.E., Ingles S.A. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol. Biomarkers Prev. 10:2001;575-579.
28. Rao A., Chang B.L., Hawkins G., Hu J.J., Rosser C.J., Hall M.C., et al. Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology. 61:2003;864-869.